Receptor, Fibroblast Growth Factor, Type 3
"Receptor, Fibroblast Growth Factor, Type 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.
Descriptor ID |
D051498
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.179 D12.776.543.750.630.442 D12.776.543.750.750.400.370.875 D12.776.624.664.700.792
|
Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 3- Receptor, Fibroblast Growth Factor, Type 3
- FGFR3 Protein
- Receptor 3, Fibroblast Growth Factor
- Fibroblast Growth Factor Receptor 3
- CD333 Antigen
- Antigen, CD333
- Fibroblast Growth Factor Receptors 3
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 3 [D08.811.913.696.620.682.725.400.179]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.543.750.630.442]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.543.750.750.400.370.875]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.624.664.700.792]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 3".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 3" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 2 | 0 | 2 |
2018 | 2 | 2 | 4 |
2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 3" by people in Profiles.
-
Erdafitinib for advanced urothelial carcinoma. Lancet Oncol. 2019 09; 20(9):e469.
-
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018 09; 119(6):707-712.
-
Noninvasive prenatal test for FGFR3-related skeletal dysplasia based on next-generation sequencing and plasma cell-free DNA: Test performance analysis and feasibility exploration. Prenat Diagn. 2018 10; 38(11):821-828.
-
RGBM: regularized gradient boosting machines for identification of the transcriptional regulators of discrete glioma subtypes. Nucleic Acids Res. 2018 04 20; 46(7):e39.
-
A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature. 2018 01 11; 553(7687):222-227.
-
Long-term follow-up of a child with Klinefelter syndrome and achondroplasia from infancy to 16 years. J Pediatr Endocrinol Metab. 2017 Jul 26; 30(7):797-803.
-
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
-
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263.
-
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs. 2012 Apr; 30(2):765-71.